Joyce Cheng

1.6k total citations
31 papers, 943 citations indexed

About

Joyce Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joyce Cheng has authored 31 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Joyce Cheng's work include Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Joyce Cheng is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Joyce Cheng collaborates with scholars based in United States, Australia and Taiwan. Joyce Cheng's co-authors include Richard Pazdur, Marc R. Theoret, Laleh Amiri‐Kordestani, Paul G. Kluetz, Rajeshwari Sridhara, Julia A. Beaver, Kirsten B. Goldberg, Gideon M. Blumenthal, Shenghui Tang and Lola A. Fashoyin‐Aje and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Joyce Cheng

29 papers receiving 923 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce Cheng United States	13	596	370	244	229	100	31	943
Anna Minchom United Kingdom	19	697 1.2×	605 1.6×	343 1.4×	154 0.7×	112 1.1×	110	1.1k
Tatiana M. Prowell United States	12	564 0.9×	414 1.1×	218 0.9×	464 2.0×	123 1.2×	24	1.0k
Geoffrey Kim United States	18	621 1.0×	354 1.0×	205 0.8×	142 0.6×	61 0.6×	29	1.0k
Reena Philip United States	16	583 1.0×	302 0.8×	402 1.6×	293 1.3×	141 1.4×	23	1.1k
Shakun Malik United States	18	454 0.8×	455 1.2×	316 1.3×	259 1.1×	97 1.0×	35	993
Ernesto Wasserman United States	17	812 1.4×	358 1.0×	418 1.7×	377 1.6×	114 1.1×	35	1.2k
Jingyu Yu United States	15	871 1.5×	439 1.2×	286 1.2×	143 0.6×	53 0.5×	27	1.3k
Desamparados Roda Spain	14	454 0.8×	188 0.5×	300 1.2×	340 1.5×	187 1.9×	39	858
Pamela Klein United States	12	770 1.3×	301 0.8×	469 1.9×	247 1.1×	182 1.8×	28	1.3k
Erin Larkins United States	14	637 1.1×	441 1.2×	286 1.2×	162 0.7×	80 0.8×	28	937

Countries citing papers authored by Joyce Cheng

Since Specialization

Citations

This map shows the geographic impact of Joyce Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Cheng more than expected).

Fields of papers citing papers by Joyce Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Cheng. The network helps show where Joyce Cheng may publish in the future.

Co-authorship network of co-authors of Joyce Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce Cheng. A scholar is included among the top collaborators of Joyce Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce Cheng. Joyce Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wedam, Suparna, Preeti Narayan, Haley Gittleman, et al.. (2025). US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 43(28). 3123–3131. 1 indexed citations

Casak, Sandra J., Vaibhav Kumar, Chi Song, et al.. (2024). FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clinical Cancer Research. 30(16). 3371–3377. 7 indexed citations

Fallah, Jaleh, Jianjin Xu, Hee‐Koung Joeng, et al.. (2024). False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations. JCO Precision Oncology. 8(8). e2400354–e2400354.

Gandhy, Shruti U., Sandra J. Casak, Sirisha L. Mushti, et al.. (2023). FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical Cancer Research. 29(20). 4027–4031. 11 indexed citations

Brewer, Jamie R., Jiaxin Fan, Joyce Cheng, et al.. (2023). FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 30(2). 269–273. 36 indexed citations

Heiss, Brian L., Jonathon Vallejo, Joyce Cheng, et al.. (2023). Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.. Journal of Clinical Oncology. 41(16_suppl). 1598–1598. 4 indexed citations

Casak, Sandra J., M. Naomi Horiba, Mengdie Yuan, et al.. (2023). FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer. Clinical Cancer Research. 29(21). 4326–4330. 21 indexed citations

Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations

Cheng, Joyce, et al.. (2022). Gastric and Duodenal Neuroendocrine Tumor Incidentally Found on Endoscopy During the Evaluation of Iron-Deficiency Anemia. Cureus. 14(2). e22208–e22208. 2 indexed citations

10.

Cheng, Joyce, et al.. (2021). Native valve endocarditis and pacemaker infection with Mycobacterium fortuitum. IDCases. 25. e01200–e01200. 4 indexed citations

11.

Gao, Jennifer, Joyce Cheng, Tatiana M. Prowell, et al.. (2021). Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 22(11). 1573–1581. 21 indexed citations

12.

Gounder, Murugesan, Munjal Patel, Nobuyuki Yamamoto, et al.. (2021). 1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma. Annals of Oncology. 32. S1124–S1125. 1 indexed citations

13.

Pelosof, Lorraine, May Tun Saung, Martha Donoghue, et al.. (2020). Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy. The Oncologist. 26(4). 318–324. 9 indexed citations

14.

Brave, Michael H., Chana Weinstock, Jamie R. Brewer, et al.. (2020). An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(18). 4717–4722. 20 indexed citations

15.

Agrawal, Sundeep, Joyce Cheng, Vishal Bhatnagar, et al.. (2020). Timing of assessments for PRO measures in advanced RCC clinical trials.. Journal of Clinical Oncology. 38(15_suppl). e19101–e19101. 1 indexed citations

16.

Brewer, Jamie R., Elaine Chang, Sundeep Agrawal, et al.. (2020). Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. Clinical Cancer Research. 26(24). 6406–6411. 6 indexed citations

17.

Gao, Jennifer, Joyce Cheng, Erik Bloomquist, et al.. (2019). CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 21(2). 250–260. 194 indexed citations

18.

Singh, Harpreet, Amanda J. Walker, Laleh Amiri‐Kordestani, et al.. (2018). U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. Clinical Cancer Research. 24(15). 3486–3491. 75 indexed citations

19.

Amiri‐Kordestani, Laleh, Joyce Cheng, Lijun Zhang, et al.. (2016). Association of clinical benefit rate (CBR) with survival: A pooled-analysis of metastatic breast cancer (MBC) trials submitted to the U.S. Food and Drug Administration (FDA).. Journal of Clinical Oncology. 34(15_suppl). e18091–e18091. 5 indexed citations

20.

Piha‐Paul, Sarina A., P.N. Munster, Antoine Hollebecque, et al.. (2015). Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. European Journal of Cancer. 51(14). 1865–1873. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact